Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Mounjaro (tirzepatide) diarrhea becomes an emergency when signs of dehydration appear: little or no urination for 8 to 12 hours, dizziness or fainting when standing, a racing heart, confusion, sunken eyes, or an inability to keep fluids down for more than 24 hours. Immediate evaluation is also warranted with bloody or black stools, severe or persistent abdominal pain, fever above 102°F, or more than 6 to 8 watery stools in a day, since these can point to pancreatitis, bowel obstruction, or infection rather than an expected side effect. The threshold differs by person, and factors such as older age, kidney disease, diuretics or blood pressure medications, and a recent dose increase all lower it, so see below for the complete list of red flags and the steps to take first. Because ordinary Mounjaro stomach upset and a true emergency can feel nearly identical in the early hours, a structured review of your specific symptoms makes the decision far clearer. Take a free, instant, online symptom check to see how your symptoms line up and get practical guidance on wh
Mounjaro (tirzepatide) is an FDA-approved injectable medication used to improve blood sugar control in people with type 2 diabetes. Like many drugs that affect digestion, diarrhea after starting Mounjaro is a known side effect. For most people, it’s mild and goes away in a few days or weeks as the body adjusts. However, diarrhea can sometimes become severe enough to cause dehydration, which may require emergency care.
Mounjaro works on two gut hormones (GLP-1 and GIP) that slow gastric emptying, reduce appetite, and improve insulin release. This change in gut motility and fluid secretion can lead to:
Expect some gastrointestinal changes during the first few weeks, especially if your dose is increasing. Keeping a food and symptom diary can help you and your healthcare provider spot patterns.
Dehydration happens when you lose more fluids and salts than you take in. With significant or prolonged diarrhea, watch for:
If you notice moderate to severe signs, you may need urgent medical attention. Dehydration can worsen quickly, especially if vomiting or fever is also present.
If your diarrhea after starting Mounjaro feels manageable, you can often handle it at home:
Your provider may suggest:
These symptoms can signal dangerously low blood pressure or electrolyte imbalances that require IV fluids and close monitoring.
Staying ahead of dehydration can keep you out of the ER. Try these tips:
If you’re unsure whether your symptoms warrant a call or an ER visit, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you understand your current risks and suggest next steps before you decide to go to urgent care or the emergency department.
Diarrhea after starting Mounjaro is common and often temporary, but it can lead to dehydration if it’s severe or prolonged. Pay close attention to your fluid balance and any warning signs. Early at-home intervention may prevent escalation, but do not hesitate to seek medical care if you develop moderate to severe dehydration symptoms.
Speak to a doctor about anything that could be life threatening or serious. Prompt treatment and honest communication with your healthcare team ensure you get the safest, most effective diabetes care.
(References)
* Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179.
* Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17. PMID: 35579691; PMCID: PMC9112245.
* Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. doi: 10.1210/jendso/bvad016. Epub 2023 Jan 26. PMID: 36789109; PMCID: PMC9915969.
* Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R, Fernández Landó L, Patel H. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023 Nov 7;330(17):1631-1640. doi: 10.1001/jama.2023.20294. PMID: 37786396; PMCID: PMC10548360.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
* Madsbad S, Holst JJ. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opin Investig Drugs. 2025 Mar;34(3):197-215. doi: 10.1080/13543784.2025.2472408. Epub 2025 Mar 1. PMID: 40022548.
* Himmerich H. [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. Nervenarzt. 2025 May;96(3):247-254. doi: 10.1007/s00115-025-01813-x. Epub 2025 Mar 5. PMID: 40042613; PMCID: PMC12058874.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.